Teruhiko Imamura

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan　- The Third Official Report From J-MACS.

BACKGROUND The nationwide impact in Japan of contemporary improvement in the clinical management of durable left ventricular assist device (LVAD), together with the introduction of the HeartMate 3 (Abbott, Pleasanton, CA, USA), on clinical outcomes remains uncertain. METHODS AND RESULTS Using the Japanese Registry fo...

Precision Use of Ivabradine in Contemporary HFrEF: From Heart Rate Reduction to Physiological Optimization.

Change in Anticoagulant Strategy During IMPELLA Support and Improved Outcomes.

BACKGROUND Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used as an anticoagulant in patients undergoing extracorporeal circulatory support who have bleeding or heparin-related adverse effects. The safety and efficacy of NM-based anticoagulation in patients receiving Impella support who deve...

Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan.

This nationwide real-world study provides the first validation of a nationally mandated DT eligibility algorithm and may support risk-based clinical decision-making in Japanese DT practice.